drugtargetreview.com3d
ITM-11 boosts survival in neuroendocrine tumour trial
ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...
Cure Today6h
Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...
Medscape7d
Drug Combo for Common Neuroendocrine Tumor: A New Standard?
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
FierceBiotech6d
Longtime manufacturer ITM's lead radiotherapy outperforms standard of care in phase 3 neuroendocrine tumor trial
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
BioPharma Dive6d
Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...